Pamiparib is a Small Molecule owned by BeiGene, and is involved in 21 clinical trials, of which 7 were completed, 12 are ongoing, and 2 are planned.

Pamiparib (BGB-290) works by inhibiting the enzymes poly (ADP-ribose) polymerase 1 and 2 (PARP-1 and PARP-2). PARP catalyses Poly(ADP-ribosyl)ation which is an immediate DNA-damage-dependent post-translational modification of histones and other nuclear proteins that contribute to the survival of injured proliferating cells. Tumor cells are more dependent on PARP. Thus the PARP serves as a target for an anticancer activity allowing tumor cells to remain as such without any repair process leading to apoptosis.

The revenue for Pamiparib is expected to reach a total of $1.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Pamiparib NPV Report.

Pamiparib was originated by BeiGene (Beijing) and is currently owned by BeiGene.

Pamiparib Overview

Pamiparib is an anti-neoplastic agent. It is formulated as capsules for oral route of administration. Pamiparib is indicated for the treatment of patients with germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy. 

Pamiparib (BGB-290) is under development for the treatment of metastatic or unresectable renal cell carcinoma, advanced or metastatic adenocarcinoma of the stomach or gastro esophageal junction, relapsed or refractory solid tumors including recurrent glioblastoma multiforme (GBM), cervical cancer, bile duct cancer, peripheral nerve sheath cancer, ovarian cancer, endometrial cancer, triple negative breast cancer, metastatic HR positive and HER2 negative breast cancer, non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, gastric cancer, leiomyosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, myxofibrosarcoma, primary peritoneal cancer, fallopian cancer, metastatic castration-resistant prostate cancer (mCRPC), high-grade glioma, low-grade glioma, colorectal cancer, metastatic adenocarcinoma of the pancreas, muscle invasive bladder cancer, transitional cell cancer(urothelial cell cancer), small-cell lung cancer and pancreatic cancer. The drug candidate is administered orally. It targets the enzymes poly (ADP-ribose) polymerase 1 and 2 (PARP-1 and PARP-2).

BeiGene Overview

BeiGene is a biotechnology company. It is specialized in the development and commercialization of immuno-oncology medicines to treat cancers. The company offers BRUKINSA, a BTK (Bruton’s tyrosine kinase) inhibitor against mantle cell lymphoma (MCL). BeiGene is investigating Zanubrutinib (BGB-3111), a small molecule inhibitor of BTK to treat B cell malignancies; Tislelizumab (BGB-A317), a monoclonal antibody targeting solid tumors and hematologic cancer; and Pamiparib (BGB-290) against solid tumor malignancies. It seeks to work in partnership with academia, biotechnology and pharmaceutical companies to develop treatments for cancer patients. The company has operations in the US, Australia, Germany, Spain Switzerland, and Italy. BeiGene is headquartered in Beijing, China.

The company reported revenues of (US Dollars) US$1,176.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$308.9 million in FY2020. The operating loss of the company was US$1,438.7 million in FY2021, compared to an operating loss of US$1,657.7 million in FY2020. The net loss of the company was US$1,413.4 million in FY2021, compared to a net loss of US$1,596.9 million in FY2020. The company reported revenues of US$387.6 million for the third quarter ended September 2022, a decrease of 40.2% over the previous quarter.

Quick View – Pamiparib

Report Segments
  • Innovator (NME)
Drug Name
  • Pamiparib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.